Work

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

Year: 2014

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0000000000000285

Authors: Ronald Natale, Fiona Blackhall, Dariusz Kowalski, Rodryg Ramlau, Gerold Bepler, Francesco Grossi, Christian Lerchenmüller, Mary Pinder-Schenck, Jörg Mezger, Sarah Danson, Shirish M. Gadgeel, Yvonne Summers, Sophie Callies, Valérie André, Mayukh Das, Michael Lahn, Denis Talbot

Institutions: Poznan University of Medical Sciences, Cedars-Sinai Medical Center, Moffitt Cancer Center, The Barbara Ann Karmanos Cancer Institute, Ospedale Policlinico San Martino, University of Sheffield, The Christie Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, St. Vincentius-Kliniken, Weston Park Cancer Centre, Eli Lilly (United States), Eli Lilly (United Kingdom), Churchill Hospital, University of Oxford

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute

Award: CANCER CENTER SUPPORT GRANT

OpenAlex ID: W1994552871

FWCI: 3.876

Cites: 16

Cited by: 50

Related to: 10